Newsletter registration

By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Your Profits Grow Sky High.

IMBA: Prevention of hereditary breast cancer is possible

(c) IMBA © IMBA

In 2010, a group of researchers at the Institute for Molecular Biotechnology (IMBA) of the Austrian Academy of Sciences in Vienna already discovered that the sex hormones can trigger breast cancer through two proteins of bone metabolism called "RANK" and "RANKL".

RANK inhibition protected mice against preliminary stages of cancer

The young scientist Verena Sigl now made the discovery that RANKL is also the main driver of genetically caused mammary cancer due to the mutated BRCA1 gene. In her study, the researcher compared mice with a mutation of the BRCA1 gene. First and foremost, RANK/RANKL were active. Carcinomas and extreme malignant changes, the preliminary stages of the carcinomas, developed in the breast. However, in those cases in which RANK was genetically inhibited, carcinomas were not found in a single mouse, and malignant changes took place much less frequently. 

In order to determine the relevance of their results for human beings, the scientists in Vienna along with researchers at the Medical University of Vienna and researchers from Toronto isolated breast tissue cells from women who had undergone preventive mastectomy because of their BRCAI mutation. After RANK was inhibited, a significant reduction of growth and spreading of breast tissue cells was observed in the human cell culture. This observation confirmed the enormous potential of an anti-RANK treatment in preventing cancer in human beings.

Preventive intake of drugs could prevent amputations

"Our finding is so exciting because there is already an approved drug on the market against RANKL, called Denosumab. It is an antibody with very few side effects, which binds tightly to RANKL and thus inhibits its ability to act”, said Verena Sigl. At present, the drug is prescribed for treating bone metastases and osteoporosis. Following the discovery made by Ms. Digl, it could be used for breast cancer prevention in the case of BRCA1 mutation carriers. From this vantage point, serious interventions such as breast amputations could be avoided.

The present work is the result of international collaboration. Scientists from Austria (IMBA, Vienna General Hospital) participated as well as researchers from Baltimore, Toronto, Canada and Barcelona.

Service: The research collaboration on the Internet: http://apps.ccge.medschl.cam.ac.uk/consortia/cimba/

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • L'open day Austria

    02.04.2019, Bologna, Italy

  • Austria jako lokalizacja biznesowa – Szanse i możliwości dla firm polskich

    03.04.2019, Katowice, Poland

Austria Map

Find the perfect location for your company

We are lucky to benefit from a lot of reserach incentives here in Austria. We are very proud to be here as Austria is an ideal location for research.

TachoEASY Austria

Logo
More testimonials

news from the business location Austria

Startup Report Austria 2018: An Overview of Key Findings

This week Florian Kandler presented his Startup Report Austria 2018. The results of the current issue of the annually published report are consistently positive. In a guest commentary for derBrutkasten Kandler selected several highlights of the report.

Startups in an enterprise environment - how companies can profit from startups

The age of digital transformation and the approach of Industry 4.0 designed to accelerate the fourth industrial revolution open up opportunities in fields such as artificial intelligence (AI) and the Internet of Things (IoT). The run towards digital business models, the collaboration with startups and the development of new innovation driver models has also impacted large European companies. Here you can read about why big firms suddenly place so much hope in startups and what they are doing.

More news All blog posts